Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer
Liu G, Jin K, Liu Z, Su X, Xu Z, Li B, Xu J, Liu H, Chang Y, Zhu Y, Xu L, Wang Z, Wang Y, Zhang W. Integration of CD4+ T cells and molecular subtype predicts benefit from PD‐L1 blockade in muscle‐invasive bladder cancer. Cancer Science 2024, 115: 1306-1316. PMID: 38402640, PMCID: PMC11007017, DOI: 10.1111/cas.16119.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerImmune checkpoint blockadeCombination of immune checkpoint blockadeCD4<sup>+</sup> T cellsFibroblast growth factor receptor 3T cellsZhongshan HospitalMolecular subtypesBladder cancerMuscle-invasive bladder cancer patientsResponses to FGFR inhibitorsCD4+ T cellsPD-L1 blockadeImmune suppressive microenvironmentTransforming growth factor-bGrowth factor BIMvigor210 cohortCheckpoint blockadePD-L1Clinical responseSuppressive microenvironmentImmune microenvironmentImmunotherapeutic responseChemotherapeutic responseClinical outcomesIntegrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer
Su X, Jin K, Guo Q, Xu Z, Liu Z, Zeng H, Wang Y, Zhu Y, Xu L, Wang Z, Chang Y, Xu J. Integrative score based on CDK6, PD-L1 and TMB predicts response to platinum-based chemotherapy and PD-1/PD-L1 blockade in muscle-invasive bladder cancer. British Journal Of Cancer 2024, 130: 852-860. PMID: 38212482, PMCID: PMC10912081, DOI: 10.1038/s41416-023-02572-9.Peer-Reviewed Original ResearchMuscle-invasive bladder cancerImmune checkpoint blockadeResponse to ICBResponse to platinum-based chemotherapyPlatinum-based chemotherapyPD-L1Bladder cancerZhongshan HospitalPD-1/PD-L1 blockadePD-1/PD-L1Cox regression analysisKaplan-Meier survivalCheckpoint blockadeCDK6 expressionResponse scoresImmune microenvironmentTherapy responseClinical outcomesPoor prognosisCancer Genome AtlasClinical significanceChemotherapyClinical relevanceProgression of cell cycleCancer treatment